Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Bibliographic Details
Main Authors:	Cassandra Rayer, Maria Nachury, Arnaud Bourreille, Xavier Roblin, Laurent Peyrin-Biroulet, Stephanie Viennot, Mathurin Flamant, David Laharie, Bénédicte Caron, Marie Dewitte, Laurent Siproudhis, Mathurin Fumery, Guillaume Bouguen
Format:	Article
Language:	English
Published:	BMC 2023-02-01
Series:	BMC Gastroenterology
Online Access:	https://doi.org/10.1186/s12876-022-02636-9

Similar Items

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
by: Rayer Cassandra, et al.
Published: (2022-12-01)

Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort studyResearch in context
by: Hongsheng Yang, et al.
Published: (2023-12-01)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
by: Kira L. Newman, et al.
Published: (2023-03-01)

Managing complex perianal disease after anti-TNF failure: Where to go next?
by: Clare Yzet, et al.
Published: (2022-01-01)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
by: Alice Burgevin, et al.
Published: (2022-11-01)

Developing anti-TNF and biologic agents.
by: Taylor, P
Published: (2011)

Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy
by: Roberto Ravasio, et al.
Published: (2023-01-01)

Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn’s Disease: A Study Based on the Korean National Database
by: Gi Hyeon Seo, et al.
Published: (2023-03-01)

Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
by: Ahmad Albshesh, et al.
Published: (2023-03-01)

Comments to “Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy”
by: Ottavio Secchi, et al.
Published: (2023-06-01)

The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding
by: Katarzyna Romanowska-Próchnicka, et al.
Published: (2021-03-01)

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
by: Javier P. Gisbert, et al.
Published: (2021-11-01)

Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study.
by: Lucille Quénéhervé, et al.
Published: (2024-01-01)

Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study
by: Lucille Quénéhervé, et al.
Published: (2024-01-01)

Inflammatory bowel disease: towards a personalized medicine
by: Mathurin Flamant, et al.
Published: (2018-01-01)

TNF-α gene polymorphisms in rheumatoid arthritis patients treated with anti-TNF-α agents: preliminary results
by: M. Fabris, et al.
Published: (2002-03-01)

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.
by: Taylor, P, et al.
Published: (2009)

Anti-TNF agents for the treatment of active non-radiographic axial spondyloarthritis
by: I. Olivieri, et al.
Published: (2013-03-01)

Effectiveness of anti-TNF-α agents in the treatment of refractory juvenile dermatomyositis
by: Ryder C, et al.
Published: (2011-09-01)

Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease
by: Corey A. Siegel, et al.
Published: (2009-07-01)

Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
by: Fragoulakis V, et al.
Published: (2015-01-01)

Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases
by: Aurelien Amiot, et al.
Published: (2015-03-01)

GOLIMUMAB IS EFFICACIOUS IN ANTI-TNF EXPERIENCED PTS WITH ACTIVE RA REGARDLESS OF TYPE OF AGENT OR REASON FOR DISCONTINUATION OF PRIOR ANTI-TNF: GO-AFTER STUDY
by: Smolen, J, et al.
Published: (2010)

Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα Immediate complications of 3,555 injections of anti-TNFα
by: Júlio César Bertacini de Moraes, et al.
Published: (2010-04-01)

Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)
by: R. Caporali, et al.
Published: (2011-09-01)

Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease
by: Haruka Miyazaki, et al.
Published: (2022-03-01)

Disseminated granuloma annulare: A cutaneous adverse effect of anti-TNF agents
by: Mondhipa Ratnarathorn, et al.
Published: (2011-01-01)

Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review
by: Mansur Saab, et al.
Published: (2015-04-01)

Anti-TNF therapy
by: Udalova, I, et al.
Published: (2016)

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China
by: Ting Zhou, et al.
Published: (2021-08-01)

Latent Tuberculosis Infection and Tuberculosis Development in Children Treated with Anti-TNF-α Agents
by: Aykut EŞKİ, et al.
Published: (2023-07-01)

Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis
by: Yimeng Gao, et al.
Published: (2022-01-01)

Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα
by: Júlio César Bertacini de Moraes, et al.

Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management
by: Cannizzaro MV, et al.
Published: (2017-04-01)

Safety of anti-TNF agents in patients with compensated cirrhosis: a case-control study
by: Nikhil Kapila, et al.
Published: (2021-10-01)

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
by: Hyun Kyeong Yoo, et al.
Published: (2022-11-01)

TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
by: Maini, R, et al.
Published: (1993)

Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry
by: Margalida Calafat, et al.
Published: (2024-01-01)

Switching anti-TNF agents is effective in most RA patients: Methotrexate determines likelihood of success
by: Appiah, L, et al.
Published: (2007)

CRITICAL ANALYSIS OF ANTI-TNF USE IN THE ERA OF NEW BIOLOGICAL AGENTS IN INFLAMMATORY BOWEL DISEASE
by: Camila Cunha Gonzaga LIMA, et al.
Published: (2020-10-01)